open-label

English

Alternative forms

Adjective

open-label (not comparable)

  1. (medicine, sciences, biology) Not withholding information from the participants of a clinical trial, as opposed to double-blind.
    • 2021 September 15, Robert Langreth, “Moderna says analysis shows COVID vaccine immunity may wane”, in The Boston Globe‎[1], archived from the original on 11 September 2026:
      The company said it found that people who received the vaccine earlier had more than a 50 percent higher rate of symptomatic breakthrough infections in July and August, compared with those who were inoculated later. The unpublished analysis is from the so-called open-label portion of Moderna’s trial, after the participants who had been given a placebo were offered the actual vaccine. Since the trial is no longer blinded, this type of additional analysis is considered less rigorous than the original study.
    • 2022 October 8, Zoë Corbyn, quoting Kathryn T Hall, “Placebos expert Kathryn T Hall: ‘The effect can rival painkillers like ibuprofen or even morphine’”, in Katharine Viner, editor, The Guardian‎[2], London: Guardian News & Media, →ISSN, →OCLC, archived from the original on 22 October 2026:
      Trademarked placebo pills such as Zeebo are also available, although they have not been tested in clinical trials. To me, what suggests a path forward are the small clinical trials of so-called open-label placebos (OLPs) – in which the patient knows they are receiving a placebo and the rationale for how they can work is explained. The trials, for conditions such as back pain, cancer-related fatigue and IBS, report significant benefit of OLPs compared with no treatment.
    • 2023 October 10, Ted J. Kaptchuk, “No Better Than a Placebo”, in The New York Times‎[3], New York, N.Y.: The New York Times Company, →ISSN, →OCLC, archived from the original on 3 May 2025:
      In another blow to the concept that concealment is required for placebo effects, my team recently published a study comparing open-label placebos and double-blind placebos in irritable bowel syndrome and found no significant difference between the two.